Per management, Inogen returned to revenue growth, improved profitability and disciplined cost management during 2024. The achievements in the quarter included the launch of Rove 4 and the receipt ...
Hosted on MSN3mon
Here's Why You Should Retain Inogen Stock in Your Portfolio NowThe company has received the FDA 510(k) clearance for its Rove 4 and launched ... channel, Inogen expects to drive higher profitability over time. The company is also seeing cost benefits in ...
Inogen, Inc. INGN recently announced a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Needham analyst Michael Matson has maintained their neutral stance on INGN stock, giving a Hold rating on January 14. Michael Matson has given his Hold rating due to a combination of factors ...
Meanwhile, INGN currently has a market capitalization of $273.4 million. In the last reported quarter, INGN delivered an earnings surprise of 50.98%. The strategic partnership between Inogen and ...
Zacks.com on MSN16d
Inogen Stock Gains Following Solid Preliminary Q4 RevenuesPer management, Inogen returned to revenue growth, improved profitability and disciplined cost management during 2024. The achievements in the quarter included the launch of Rove 4 and the receipt of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results